NCT03015402View on ClinicalTrials.gov

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Pulmonary Hypertension SecondaryHeart Failure
Interventions
DRUG

Sodium Nitrite

40 mg PO (by mouth) TID (three times each day) for 10 weeks

DRUG

Placebo Oral Capsule

Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Pittsburgh

OTHER

NCT03015402 - Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter